1 Includes chronic gastritis, gastritis, erosive gastritis, and reflux gastritis
DXA analysis of a 140-participant subgroup showed that total lean body mass decreased by 9.7% over 68 weeks, while fat mass decreased by 19.3%
This approach not only enhanced risk stratification beyond classical clinical markers but also revealed novel metabolic features with potential relevance as therapeutic targets, many of which were not captured through traditional enrichment or univariate analyses
Nausea on GLP-1s happens because the medication slows down how quickly your stomach empties, which makes you feel full faster
However, this also comes with: Higher efficacy: Substantially greater weight loss More side effects: Increased GI symptoms and dysesthesia Unknown long-term effects: Retatrutide's extended safety profile is still being evaluated What's Next: The TRIUMPH Program Timeline TRIUMPH-4 is just the beginning
This holds particular promise for: Older adults facing chronic low-grade inflammation Immunocompromised individuals Age-related decline in vaccine efficacy Oncology patients recovering from chemo- or radiotherapy-induced immune depletion In the next section, we turn to the brain by examining Epitalons neuroprotective potential and early findings on cognitive health and neurodegeneration